Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melinjo seed ethyl acetate fraction is an **early-stage natural product extract** prepared from the seeds of *Gnetum gnemon* through ethanol extraction followed by ethyl acetate fractionation. It is best characterized as a **small molecule phytochemical mixture** enriched in polyphenolic constituents, including **resveratrol derivatives** such as **gnetin C** and **gnemonoside A**. Preclinical academic studies have reported **antioxidant activity**, **cytotoxicity against cancer cell lines** including breast cancer MCF-7 and cervical cancer HeLa cells, and **angiotensin-converting enzyme inhibition**, suggesting possible antineoplastic and antihypertensive potential. However, it does **not appear to have an identified commercial sponsor, brand, manufacturing program, or clinical-stage development**, and the observed activity is better understood as arising from a multi-constituent phenolic extract rather than a single defined molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on melinjo seed ethyl acetate fraction.